JP2022515611A5 - - Google Patents
Info
- Publication number
- JP2022515611A5 JP2022515611A5 JP2021535639A JP2021535639A JP2022515611A5 JP 2022515611 A5 JP2022515611 A5 JP 2022515611A5 JP 2021535639 A JP2021535639 A JP 2021535639A JP 2021535639 A JP2021535639 A JP 2021535639A JP 2022515611 A5 JP2022515611 A5 JP 2022515611A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024196389A JP7818681B2 (ja) | 2018-12-19 | 2024-11-11 | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862782142P | 2018-12-19 | 2018-12-19 | |
| US62/782,142 | 2018-12-19 | ||
| US201962815861P | 2019-03-08 | 2019-03-08 | |
| US62/815,861 | 2019-03-08 | ||
| PCT/US2019/067109 WO2020132024A1 (en) | 2018-12-19 | 2019-12-18 | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024196389A Division JP7818681B2 (ja) | 2018-12-19 | 2024-11-11 | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022515611A JP2022515611A (ja) | 2022-02-21 |
| JPWO2020132024A5 JPWO2020132024A5 (https=) | 2022-12-19 |
| JP2022515611A5 true JP2022515611A5 (https=) | 2022-12-19 |
| JP7588586B2 JP7588586B2 (ja) | 2024-11-22 |
Family
ID=69182675
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021535639A Active JP7588586B2 (ja) | 2018-12-19 | 2019-12-18 | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
| JP2024196389A Active JP7818681B2 (ja) | 2018-12-19 | 2024-11-11 | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024196389A Active JP7818681B2 (ja) | 2018-12-19 | 2024-11-11 | 二重特異性抗ｍｕｃ１６×抗ｃｄ２８抗体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11453721B2 (https=) |
| EP (1) | EP3898695A1 (https=) |
| JP (2) | JP7588586B2 (https=) |
| KR (1) | KR20210104758A (https=) |
| CN (1) | CN113166268B (https=) |
| AU (1) | AU2019405736B2 (https=) |
| BR (1) | BR112021010457A2 (https=) |
| CA (1) | CA3123420A1 (https=) |
| CL (1) | CL2021001573A1 (https=) |
| CO (1) | CO2021007077A2 (https=) |
| IL (1) | IL283493A (https=) |
| MA (1) | MA54539A (https=) |
| MX (1) | MX2021006971A (https=) |
| MY (1) | MY208537A (https=) |
| PH (1) | PH12021551238A1 (https=) |
| SG (1) | SG11202105948TA (https=) |
| WO (1) | WO2020132024A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019246514A1 (en) * | 2018-06-21 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| CA3192204A1 (en) | 2020-08-19 | 2022-02-24 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
| CN111925990B (zh) * | 2020-09-02 | 2022-08-26 | 北京立康生命科技有限公司 | 一种针对卵巢癌的Anti-MUC16 CAR-T细胞及其制备方法 |
| US11905332B2 (en) | 2020-09-18 | 2024-02-20 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind CD38 and/or CD28, and uses thereof |
| EP4274901A1 (en) | 2021-01-11 | 2023-11-15 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
| EP4472646A1 (en) | 2022-02-01 | 2024-12-11 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
| CN119110809A (zh) | 2022-02-23 | 2024-12-10 | Xencor股份有限公司 | 抗CD28 x抗PSMA抗体 |
| IL314916A (en) | 2022-03-07 | 2024-10-01 | Novimmune Sa | Bispecific CD28 antibodies for targeted T cell activation |
| CN119095873A (zh) | 2022-03-14 | 2024-12-06 | 拉姆卡普生物伽马股份公司 | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
| TW202413416A (zh) * | 2022-04-11 | 2024-04-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途 |
| WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024084052A1 (en) | 2022-10-21 | 2024-04-25 | Novimmune Sa | Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| TW202539732A (zh) | 2023-11-29 | 2025-10-16 | 美商再生元醫藥公司 | 以雙特異性抗muc16×抗cd28抗體與抗pd-1抗體之組合或與雙特異性抗muc16×抗cd3抗體之組合治療復發性卵巢癌及子宮內膜癌之方法 |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2026078067A1 (en) | 2024-10-08 | 2026-04-16 | Novimmune Sa | Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US20040116675A1 (en) | 2001-12-14 | 2004-06-17 | Tso J. Jun | Silenced anti-cd28 antibodies and use thereof |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| ES2398076T3 (es) | 2006-06-02 | 2013-03-13 | Regeneron Pharmaceuticals, Inc. | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| SI2501817T2 (sl) | 2010-02-08 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Miš z navadno lahko verigo |
| US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| US9682143B2 (en) * | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| EP3046938B1 (en) | 2013-09-16 | 2019-12-04 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Bi- or multispecific polypeptides binding immune effector cell surface antigens and hbv antigens for treating hbv infections and associated conditions |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| WO2016019969A1 (en) * | 2014-08-08 | 2016-02-11 | Ludwig-Maximilians-Universität München | Subcutaneously administered bispecific antibodies for use in the treatment of cancer |
| LT3353212T (lt) | 2015-09-23 | 2021-12-27 | Regeneron Pharmaceuticals, Inc. | Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas |
| MY194596A (en) | 2016-09-23 | 2022-12-06 | Regeneron Pharma | Bi Specific Anti-Muc16-CD3 Antibodies And Anti-Muc16 Drug Conjugates |
| MX2019003325A (es) | 2016-09-23 | 2019-08-05 | Regeneron Pharma | Anticuerpos anti-steap2, conjugados anticuerpo-farmaco, y moleculas de fijacion al antigeno biespecificas que se fijan a steap2 y cd3, y usos de estos. |
-
2019
- 2019-12-18 US US16/719,273 patent/US11453721B2/en active Active
- 2019-12-18 SG SG11202105948TA patent/SG11202105948TA/en unknown
- 2019-12-18 WO PCT/US2019/067109 patent/WO2020132024A1/en not_active Ceased
- 2019-12-18 MX MX2021006971A patent/MX2021006971A/es unknown
- 2019-12-18 JP JP2021535639A patent/JP7588586B2/ja active Active
- 2019-12-18 BR BR112021010457-7A patent/BR112021010457A2/pt unknown
- 2019-12-18 EP EP19839545.1A patent/EP3898695A1/en active Pending
- 2019-12-18 CN CN201980080509.2A patent/CN113166268B/zh active Active
- 2019-12-18 CA CA3123420A patent/CA3123420A1/en active Pending
- 2019-12-18 MY MYPI2021002954A patent/MY208537A/en unknown
- 2019-12-18 KR KR1020217021119A patent/KR20210104758A/ko active Pending
- 2019-12-18 AU AU2019405736A patent/AU2019405736B2/en active Active
- 2019-12-18 MA MA054539A patent/MA54539A/fr unknown
-
2021
- 2021-05-27 IL IL283493A patent/IL283493A/en unknown
- 2021-05-28 PH PH12021551238A patent/PH12021551238A1/en unknown
- 2021-05-28 CO CONC2021/0007077A patent/CO2021007077A2/es unknown
- 2021-06-15 CL CL2021001573A patent/CL2021001573A1/es unknown
-
2022
- 2022-08-17 US US17/890,078 patent/US20230279113A1/en active Pending
-
2024
- 2024-11-11 JP JP2024196389A patent/JP7818681B2/ja active Active